Abstract
The present study evaluated serial serum measurements of tissue polypeptide-specific antigen (TPS) in comparison with prostate-specific antigen (PSA) for assessment of tumour progression in patients with advanced prostate cancer receiving intermittent androgen suppression therapy (IAS). Twenty-three men were recruited into an IAS trial consisting of an initial 8 months of androgen suppression, followed by cycles of treatment cessation and resumption of therapy upon increases of PSA > 20 ng ml(-1) to prolong the hormone responsiveness of the tumour cells. Periods of androgen suppression resulted in reversible reduction in serum testosterone (< 1.8 nmol I(-1)) and PSA (< 4 ng ml(-1)) and decreases in tumour volume (mean reduction for first cycle 24 +/- 10%), indicating partial growth arrest and apoptotic regression of the tumours. In contrast to PSA values, non-specifically elevated TPS values were found in 8 of 23 patients. In 15 of 23 patients, TPS fell during periods of apoptotic tumour regression and increased simultaneously with testosterone and preceded the increases in PSA by 2 months during the period of treatment cessation. Although TPS represents a highly sensitive marker of tumour proliferation in this IAS clinical model of controlled tumour regression and regrowth, its low specificity compared with PSA limits its usefulness to monitoring of prostate cancer patients with proven absence of non-specific elevations of this marker.
Full text
PDF



Selected References
These references are in PubMed. This may not be the complete list of references from this article.
- Akakura K., Bruchovsky N., Goldenberg S. L., Rennie P. S., Buckley A. R., Sullivan L. D. Effects of intermittent androgen suppression on androgen-dependent tumors. Apoptosis and serum prostate-specific antigen. Cancer. 1993 May 1;71(9):2782–2790. doi: 10.1002/1097-0142(19930501)71:9<2782::aid-cncr2820710916>3.0.co;2-z. [DOI] [PubMed] [Google Scholar]
- Bruchovsky N., Goldenberg S. L., Rennie P. S., Gleave M. Theoretische Uberlegungen und erste klinische Ergebnisse mit intermittierender Hormonbehandlung bei Patienten mit einem fortgeschrittenen Prostatakarzinom. Urologe A. 1995 Sep;34(5):389–392. [PubMed] [Google Scholar]
- Bruchovsky N., Rennie P. S., Coldman A. J., Goldenberg S. L., To M., Lawson D. Effects of androgen withdrawal on the stem cell composition of the Shionogi carcinoma. Cancer Res. 1990 Apr 15;50(8):2275–2282. [PubMed] [Google Scholar]
- Børmer O. P. From tissue polypeptide antigen to specific cytokeratin assays. Tumour Biol. 1994;15(4):185–187. [PubMed] [Google Scholar]
- Denis L. Commentary on maximal androgen blockade in prostate cancer: a theory to put into practice? Prostate. 1995 Nov;27(5):233–240. doi: 10.1002/pros.2990270502. [DOI] [PubMed] [Google Scholar]
- Kornek G., Schenk T., Raderer M., Djavarnmad M., Scheithauer W. Tissue polypeptide-specific antigen (TPS) in monitoring palliative treatment response of patients with gastrointestinal tumours. Br J Cancer. 1995 Jan;71(1):182–185. doi: 10.1038/bjc.1995.37. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Leo M. E., Bilhartz D. L., Bergstralh E. J., Oesterling J. E. Prostate specific antigen in hormonally treated stage D2 prostate cancer: is it always an accurate indicator of disease status? J Urol. 1991 Apr;145(4):802–806. doi: 10.1016/s0022-5347(17)38456-2. [DOI] [PubMed] [Google Scholar]
- Marrink J., Oosterom R., Bonfrer H. M., Schröder F. H., Mensink H. J. Tissue polypeptide-specific antigen: a discriminative parameter between prostate cancer and benign prostatic hypertrophy. Eur J Cancer. 1993;29A(4):570–571. doi: 10.1016/s0959-8049(05)80153-4. [DOI] [PubMed] [Google Scholar]
- Miller J. I., Ahmann F. R., Drach G. W., Emerson S. S., Bottaccini M. R. The clinical usefulness of serum prostate specific antigen after hormonal therapy of metastatic prostate cancer. J Urol. 1992 Mar;147(3 Pt 2):956–961. doi: 10.1016/s0022-5347(17)37432-3. [DOI] [PubMed] [Google Scholar]
- Oesterling J. E. Prostate specific antigen: a critical assessment of the most useful tumor marker for adenocarcinoma of the prostate. J Urol. 1991 May;145(5):907–923. doi: 10.1016/s0022-5347(17)38491-4. [DOI] [PubMed] [Google Scholar]
- Plebani M., Basso D., Navaglia F., De Paoli M., Tommasini A., Cipriani A. Clinical evaluation of seven tumour markers in lung cancer diagnosis: can any combination improve the results? Br J Cancer. 1995 Jul;72(1):170–173. doi: 10.1038/bjc.1995.296. [DOI] [PMC free article] [PubMed] [Google Scholar]
- Tarle M., Frković-Grazio S., Kraljić I., Kovacić K. A more objective staging of advanced prostate cancer--routine recognition of malignant endocrine structures: the assessment of serum TPS, PSA, and NSE values. Prostate. 1994;24(3):143–148. doi: 10.1002/pros.2990240308. [DOI] [PubMed] [Google Scholar]
- Tarle M., Kovacić K., Kastelan M. Correlation of cell proliferation marker (TPS), natural killer (NK) activity and tumor load serotest (PSA) in untreated and treated prostatic tumors. Anticancer Res. 1993 Jan-Feb;13(1):215–218. [PubMed] [Google Scholar]
- Tarle M. Serial measurements of tissue polypeptide specific antigen (TPS), PSA, PAP and CEA serotest values in treated patients with primary and metastatic prostate cancer. Anticancer Res. 1993 May-Jun;13(3):769–777. [PubMed] [Google Scholar]
- Theyer G., Hamilton G. Role of multidrug resistance in tumors of the genitourinary tract. Urology. 1994 Dec;44(6):942–950. doi: 10.1016/s0090-4295(94)80191-6. [DOI] [PubMed] [Google Scholar]
- Yagoda A., Petrylak D. Cytotoxic chemotherapy for advanced hormone-resistant prostate cancer. Cancer. 1993 Feb 1;71(3 Suppl):1098–1109. doi: 10.1002/1097-0142(19930201)71:3+<1098::aid-cncr2820711432>3.0.co;2-g. [DOI] [PubMed] [Google Scholar]
